The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy

Detalhes bibliográficos
Autor(a) principal: Hasenclever, Lia
Data de Publicação: 2008
Outros Autores: Paranhos, Julia, Paiva, Vitor
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: RECIIS (Online)
Texto Completo: https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848
Resumo: The pharmaceutical sector is characterized by a great oligopoly, with small and big transnational companies which operate in several countries and perform high levels of investment in research and development, which imply great barriers to the entry of new companies. It’s a sector in which appropriation of knowledge occurs principally through the patent of new drugs. Such patents allow monopoly of the developer company of the product over the same product during a determined period. The possibility of abusive practices from this monopoly leads the authorities to take measures for the control of prices and to guarantee the finitude of the patent. Therefore, the United States and the European Union are pressuring the other countries for the establishment of new measures, which go beyond the TRIPS Agreement, such as secrecy of drugs registration, in order to enlarge the monopoly of big pharmaceutical companies and retard the entry of generics.
id FIOCRUZ-6_e1c0dd7c17b26544ff1d5104b547087b
oai_identifier_str oai:www.reciis.icict.fiocruz.br:article/848
network_acronym_str FIOCRUZ-6
network_name_str RECIIS (Online)
repository_id_str
spelling The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policyA extensão da propriedade intelectual através do sigilo do registro de medicamentos: empecilhos à política de medicamentos genéricosIntellectual propertypatentgenericsdrug registrationpropriedade intelectualpatentegenéricosregistro de medicamentosThe pharmaceutical sector is characterized by a great oligopoly, with small and big transnational companies which operate in several countries and perform high levels of investment in research and development, which imply great barriers to the entry of new companies. It’s a sector in which appropriation of knowledge occurs principally through the patent of new drugs. Such patents allow monopoly of the developer company of the product over the same product during a determined period. The possibility of abusive practices from this monopoly leads the authorities to take measures for the control of prices and to guarantee the finitude of the patent. Therefore, the United States and the European Union are pressuring the other countries for the establishment of new measures, which go beyond the TRIPS Agreement, such as secrecy of drugs registration, in order to enlarge the monopoly of big pharmaceutical companies and retard the entry of generics.O setor farmacêutico é caracterizado por um grande oligopólio, com poucas e grandes empresas transnacionais que atuam em diversos países e realizam altos níveis de investimento em pesquisa e desenvolvimento, que implicam em grandes barreiras à entrada de novas empresas. Trata-se de um setor em que a apropriação do conhecimento ocorre principalmente através da patente de novos medicamentos. Tais patentes permitem o monopólio da empresa desenvolvedora do produto sobre o mesmo durante um período determinado. A possibilidade de práticas abusivas a partir deste monopólio leva as autoridades a tomarem medidas para controle de preços e para garantirem a finitude da patente. No entanto, os Estados Unidos e a União Européia vêm pressionando os demais países para o estabelecimento de novas medidas, que vão além do Acordo TRIPS, como o sigilo do registro de medicamenInstituto de Comunicação e Informação Científica e Tecnológica em Saúde (Icict/Fiocruz)2008-07-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionAvaliado pelos paresapplication/pdfapplication/pdfhttps://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/84810.3395/reciis.v2i2.848Revista Eletrônica de Comunicação, Informação & Inovação em Saúde; Vol. 2 No. 2 (2008)Revista Eletrônica de Comunicação, Informação e Inovação em Saúde; Vol. 2 Núm. 2 (2008)Revue de la Communication, de l'Information et de l'Innovation en santé; Vol. 2 No 2 (2008)Revista Eletrônica de Comunicação, Informação & Inovação em Saúde; v. 2 n. 2 (2008)1981-6278reponame:RECIIS (Online)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporenghttps://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848/1490https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848/1662Hasenclever, LiaParanhos, JuliaPaiva, Vitorinfo:eu-repo/semantics/openAccess2022-08-11T14:24:54Zoai:www.reciis.icict.fiocruz.br:article/848Revistahttps://www.reciis.icict.fiocruz.br/index.php/reciishttps://www.reciis.icict.fiocruz.br/index.php/reciis/oaireciis@icict.fiocruz.br1981-62781981-6278opendoar:2022-08-11T14:24:54RECIIS (Online) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.none.fl_str_mv The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy
A extensão da propriedade intelectual através do sigilo do registro de medicamentos: empecilhos à política de medicamentos genéricos
title The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy
spellingShingle The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy
Hasenclever, Lia
Intellectual property
patent
generics
drug registration
propriedade intelectual
patente
genéricos
registro de medicamentos
title_short The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy
title_full The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy
title_fullStr The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy
title_full_unstemmed The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy
title_sort The extension of intellectual property through secrecy of drugs registration: obstacles to the generic drug policy
author Hasenclever, Lia
author_facet Hasenclever, Lia
Paranhos, Julia
Paiva, Vitor
author_role author
author2 Paranhos, Julia
Paiva, Vitor
author2_role author
author
dc.contributor.author.fl_str_mv Hasenclever, Lia
Paranhos, Julia
Paiva, Vitor
dc.subject.por.fl_str_mv Intellectual property
patent
generics
drug registration
propriedade intelectual
patente
genéricos
registro de medicamentos
topic Intellectual property
patent
generics
drug registration
propriedade intelectual
patente
genéricos
registro de medicamentos
description The pharmaceutical sector is characterized by a great oligopoly, with small and big transnational companies which operate in several countries and perform high levels of investment in research and development, which imply great barriers to the entry of new companies. It’s a sector in which appropriation of knowledge occurs principally through the patent of new drugs. Such patents allow monopoly of the developer company of the product over the same product during a determined period. The possibility of abusive practices from this monopoly leads the authorities to take measures for the control of prices and to guarantee the finitude of the patent. Therefore, the United States and the European Union are pressuring the other countries for the establishment of new measures, which go beyond the TRIPS Agreement, such as secrecy of drugs registration, in order to enlarge the monopoly of big pharmaceutical companies and retard the entry of generics.
publishDate 2008
dc.date.none.fl_str_mv 2008-07-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Avaliado pelos pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848
10.3395/reciis.v2i2.848
url https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848
identifier_str_mv 10.3395/reciis.v2i2.848
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848/1490
https://www.reciis.icict.fiocruz.br/index.php/reciis/article/view/848/1662
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Instituto de Comunicação e Informação Científica e Tecnológica em Saúde (Icict/Fiocruz)
publisher.none.fl_str_mv Instituto de Comunicação e Informação Científica e Tecnológica em Saúde (Icict/Fiocruz)
dc.source.none.fl_str_mv Revista Eletrônica de Comunicação, Informação & Inovação em Saúde; Vol. 2 No. 2 (2008)
Revista Eletrônica de Comunicação, Informação e Inovação em Saúde; Vol. 2 Núm. 2 (2008)
Revue de la Communication, de l'Information et de l'Innovation en santé; Vol. 2 No 2 (2008)
Revista Eletrônica de Comunicação, Informação & Inovação em Saúde; v. 2 n. 2 (2008)
1981-6278
reponame:RECIIS (Online)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str RECIIS (Online)
collection RECIIS (Online)
repository.name.fl_str_mv RECIIS (Online) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv reciis@icict.fiocruz.br
_version_ 1798942463985975296

Registros relacionados